BerandaEBS • NYSE
add
Emergent Biosolutions Inc
$4,79
Setelah Jam Perdagangan Normal:(1,25%)+0,060
$4,85
Tutup: 6 Mei, 19.10.33 GMT-4 · USD · NYSE · Pernyataan Penyangkalan
Tutup sebelumnya
$4,95
Rentang hari
$4,71 - $4,97
Rentang tahun
$3,91 - $15,10
Kapitalisasi pasar
260,27Â jt USD
Volume Rata-Rata
1,16Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NYSE
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Des 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 194,70Â jt | -29,61% |
Biaya operasional | 140,80Â jt | -33,40% |
Laba bersih | -31,30Â jt | 36,77% |
Margin laba bersih | -16,08 | 10,17% |
Penghasilan per saham | 0,05 | 106,49% |
EBITDA | 21,00Â jt | 255,56% |
Tarif pajak efektif | -13,41% | — |
Neraca
Total aset
Total liabilitas
(USD) | Des 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 99,50Â jt | -10,92% |
Total aset | 1,39Â M | -23,78% |
Total liabilitas | 906,90Â jt | -22,74% |
Total ekuitas | 482,80 jt | — |
Saham yang beredar | 54,34 jt | — |
Harga terhadap nilai buku | 0,56 | — |
Tingkat pengembalian aset | -0,75% | — |
Tingkat pengembalian modal | -0,92% | — |
Arus Kas
Perubahan kas bersih
(USD) | Des 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -31,30Â jt | 36,77% |
Kas dari operasi | -79,90Â jt | -348,91% |
Kas dari investasi | 28,60Â jt | 350,88% |
Kas dari pembiayaan | 500,00Â rb | -89,36% |
Perubahan kas bersih | -50,80Â jt | -312,55% |
Arus kas bebas | -5,54Â jt | -113,72% |
Tentang
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Didirikan
5 Sep 1998
Kantor pusat
Karyawan
900